Education
About Us
Working with TipRanks
Follow Us
Third Harmonic Bio, Inc. (THRD)
NASDAQ:THRD
RESEARCH TOOLSreports
THRD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.18 - $16.94
Previous CloseN/A
Volume85.60K
Average Volume (3M)834.66K
Market Cap
$229.58M
Enterprise Value$179.77M
Total Cash (Recent Filing)$285.06M
Total Debt (Recent Filing)$3.21M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
May 08, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding45,103,897
10 Day Avg. Volume1,813,732
30 Day Avg. Volume834,660
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.24
Forecast
1Y Price Target
$5.24Price Target Upside2.34% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Distribution To ShareholdersThe distribution to shareholders is estimated to be in the range between ~$5.13-$5.33/share.
Pharmacokinetics And PharmacodynamicsTHB335 demonstrated strong pharmacokinetics and pharmacodynamics with deep serum tryptase reductions.
Potential Study InitiationThe company is preparing for a potential Phase 2 study for THB335 in chronic spontaneous urticaria, aiming for initiation in mid-2025.
Bears Say
Company LiquidationThird Harmonic Bio announced plans to liquidate and dissolve the company.
Safety ConcernsSafety concerns from Phase 1 data, including reductions in hemoglobin and neutrophils, likely limit the use of higher doses of THB335.
Stock DowngradeThe stock rating for THRD has been downgraded to Hold due to a lack of clarity on the development path for THB335.
---
Ownership Overview
37.63% Insiders
12.10% Mutual Funds
<0.01% Other Institutional Investors
45.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
THRD FAQ
What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Third Harmonic Bio, Inc. lowest stock price was $3.18 and its highest was $16.94 in the past 12 months.
What is Third Harmonic Bio, Inc.’s market cap?
Third Harmonic Bio, Inc.’s market cap is $229.58M.
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
Third Harmonic Bio, Inc.’s upcoming earnings report date is May 08, 2025 which is in 22 days.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Third Harmonic Bio, Inc. released its earnings results on Mar 27, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.362 by $0.072.
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Undervalued.
Does Third Harmonic Bio, Inc. pay dividends?
Third Harmonic Bio, Inc. does not currently pay dividends.
What is Third Harmonic Bio, Inc.’s EPS estimate?
Third Harmonic Bio, Inc.’s EPS estimate is -0.27.
How many shares outstanding does Third Harmonic Bio, Inc. have?
Third Harmonic Bio, Inc. has 45,103,897 shares outstanding.
What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
Third Harmonic Bio, Inc. reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.362. Following the earnings report the stock price went down -1.133%.
Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
Currently, no hedge funds are holding shares in THRD
---
Third Harmonic Bio, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.24 (2.34% Upside)
$5.24 (2.34% Upside)
Blogger Sentiment
Bullish
THRD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 575.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.57%
12-Months-Change
Fundamentals
Return on Equity
-16.41%
Trailing 12-Months
Asset Growth
6.08%
Trailing 12-Months
Company Description
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
---
THRD Stock 12 Month Forecast
Average Price Target
$5.24
▲(2.34% Upside)
Technical Analysis
Cardiff Oncology
―
Neurogene
―
Annexon Biosciences
―
Innate Pharma
―
Design Therapeutics
―
Best Analysts Covering THRD
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+2.30%
reiterated a buy rating 2 months ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +2.30% per trade.
---